Tratamiento de COVID-19 en Panamá. La historia del inicio, estudio PanaCovid2020
[Treatment of COVID-19 in Panama. The story of the beginning, PanaCovid2020 study]Descargas
Archivos adicionales
Resumen
Antecedentes En Panamá, durante los primeros cinco meses de pandemia, se reportaron 65,256 casos y 1,421 fallecimientos por COVID-19. Los tratamientos utilizados en pacientes hospitalizados durante este periodo fueron variando en la medida que surgía evidencia científica. Metodología Presentamos un estudio multicéntrico observacional, descriptivo, de corte transversal y retrospectivo de la terapéutica administrada en pacientes hospitalizados con COVID-19 en siete centros estatales de la República de Panamá, entre el 1 de marzo al 31 de julio de 2020. Se analizó el resultado de recuperado o fallecido en relación al uso de hidroxicloroquina, heparinas y esteroides. Resultados Se revisaron 837 expedientes. 60.7% pacientes eran hombres y la mediana de edad fue 53.6 años. Los tratamientos más utilizados fueron heparinas 84.7%, esteroides sistémicos 76.5%, azitromicina 65.5% e hidroxicloroquina en 41.1%. La frecuencia de uso de oxigenoterapia fue de cánula nasal 73,2%, máscara facial con reservorio 39%, cánula de alto flujo 8.9%, ventilación mecánica no invasiva 11.1% y ventilación invasiva en el 15.3%. Los esteroides mostraron mayor tasa de recuperación (OR 1.72 [1.16-2.54).
Conclusiones El reto de abordar una nueva enfermedad, sin tratamiento conocido, con evolución y desenlace variable, llevó a la comunidad médica a utilizar medicamentos empíricos con potencial terapéutico incierto. Destacamos que desde muy temprano se administró esteroides sistémicos, heparinas y tocilizumab; actualmente con beneficios para pacientes con requerimientos de hospitalización. Además, se empleó técnicas de oxigenación, como la cánula de alto flujo y ventilación mecánica no invasiva, con dudosa efectividad; pero que hoy ya tienen un rol estudiado en la falla respiratoria por COVID-19.
Abstract
Background: In Panama, during the first five months of the pandemic, 65,256 cases and 1,421 deaths due to COVID-19 were reported. The treatments used in hospitalized patients during this period varied as scientific evidence emerged. Methodology: We present a retrospective, descriptive, cross-sectional, observational, descriptive, multicenter study of the therapeutics administered in hospitalized patients with COVID-19 in seven state centers in the Republic of Panama, between March 1 and July 31, 2020. The outcome of recovered or deceased was analyzed in relation to the use of hydroxychloroquine, heparins and steroids. Results: A total of 837 files were reviewed. 60.7% of patients were men and the median age was 53.6 years. The most commonly used treatments were heparins 84.7%, systemic steroids 76.5%, azithromycin 65.5% and hydroxychloroquine in 41.1%. The frequency of oxygen therapy use was nasal cannula 73.2%, face mask with reservoir 39%, high-flow cannula 8.9%, noninvasive mechanical ventilation 11.1% and invasive ventilation in 15.3%. Steroids showed higher recovery rate (OR 1.72 [1.16-2.54).
Conclusions: The challenge of dealing with a new disease, without known treatment, with variable evolution and outcome, led the medical community to use empirical drugs with uncertain therapeutic potential. We highlight the early administration of systemic steroids, heparins and tocilizumab; currently with benefits for patients requiring hospitalization. In addition, oxygenation techniques were used, such as high-flow cannula and noninvasive mechanical ventilation, with doubtful effectiveness, but which today have a studied role in respiratory failure due to COVID-19.
Citas
[1] World Health Organization. Coronavirus disease (COVID-19). Situation report [Internet]. [cited 2022 Sep 11]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
[2] Ministerio de salud de Panamá. BITÁCORA DEL EVENTO PANDÉMICO COVID-19. 2020 [cited 2022 Aug 14]; Available from: https://www.minsa.gob.pa/sites/default/files/general/bitacora_covid-19_segundo_cuatrimestre.pdf
[3] Llover MN, Cols Jiménez M. Terapéutica en APS Estado actual de los tratamientos para la COVID-19 Puntos para una lectura rápida. Vol. 28. 2021.
[4] Şimşek Yavuz S, Ünal S. Antiviral treatment of covid-19. Vol. 50, Turkish Journal of Medical Sciences. Turkiye Klinikleri; 2020. p. 611–9.
[5] Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Jul 1;56(1).
[6] National Institutes of Health. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet]. [cited 2022 Aug 14]. Available from: https://www.covid19treatmentguidelines.nih.gov
[7] Noriega-Aguirre L, Alvear M, Villarreal O, Rueda E, Rodríguez-Osorio R, Arroyo R, et al. ARTÍCULO ORIGINAL [Internet]. Available from: https://orcid.org/0000-0001-6643-5910
[8] Dexamethasone in Hospitalized Patients with Covid-19. New England Journal of Medicine [Internet]. 2021 Feb 25;384(8):693–704. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2021436
[9] Malas MB, Naazie IN, Elsayed N, Mathlouthi A, Marmor R, Clary B. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: A systematic review and meta-analysis. EClinicalMedicine. 2020;29–30.
[10] Gratz J, Wiegele M, Maleczek M, Herkner H, Schöchl H, Chwala E, et al. Risk of Clinically Relevant Venous Thromboembolism in Critically Ill Patients With COVID-19: A Systematic Review and Meta-Analysis. Vol. 8, Frontiers in Medicine. 2021.
[11] Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis. Res Pract Thromb Haemost. 2020;4(7).
[12] Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020 Jun 1;57:279–83.
[13] WHO Solidarity Trial Consortium. Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. [cited 2022 Aug 14]; Available from: 10.1056/NEJMoa2023184
[14] Ginsburg AS, Klugman KP. COVID-19 pneumonia and the appropriate use of antibiotics. Vol. 8, The Lancet Global Health. Elsevier Ltd; 2020. p. e1453–4.
[15] Yusuf I, Sarkinfada F. Gaps in the implementation of covid-19 mitigation measures could lead to development of new strains of antimicrobial resistant pathogens: Nigerian perspective. Vol. 40, Pan African Medical Journal. African Field Epidemiology Network; 2021.
[16] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. New England Journal of Medicine. 2020 May 7;382(19):1787–99.
[17] Cortegiani A, Ippolito M, Greco M, Granone V, Protti A, Gregoretti C, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Vol. 27, Pulmonology. Elsevier Espana S.L.U; 2021. p. 52–66.
[18] Sciascia S, Aprà F, Baffa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. 2020.
[19] Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, et al. Ivermectin for Prevention and Treatment of COVID-19 Infection: A Systematic Review, Meta-analysis, and Trial Sequential Analysis to Inform Clinical Guidelines. Am J Ther [Internet]. 2021;28:434–60. Available from: https://www.gofundme.
[20] Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020 Jun 1;178.
[21] Bae M, Kim H. Mini-Review on the Roles of Vitamin C, Vitamin D, and Selenium in the Immune System against COVID-19. Vol. 25, Molecules (Basel, Switzerland). NLM (Medline); 2020.
[22] Holford P, Carr AC, Jovic TH, Ali SR, Whitaker IS, Marik PE, et al. Vitamin C—An adjunctive therapy for respiratory infection, sepsis and COVID-19. Vol. 12, Nutrients. MDPI AG; 2020. p. 1–17.
[23] Hadizadeh F. Supplementation with vitamin D in the COVID-19 pandemic? Nutr Rev. 2021 Feb 1;79(2):200–8.
[24] Zemb P, Bergman P, Camargo CA, Cavalier E, Cormier C, Courbebaisse M, et al. Vitamin D deficiency and the COVID-19 pandemic. J Glob Antimicrob Resist. 2020 Sep 1;22:133–4.
[25] Wang Z, Wang Y, Yang Z, Wu H, Liang J, Liang H, et al. The use of non-invasive ventilation in COVID-19: A systematic review. Vol. 106, International Journal of Infectious Diseases. Elsevier B.V.; 2021. p. 254–61.
[26] Cinesi Gómez C, Peñuelas Rodríguez Ó, Luján Torné M, Egea Santaolalla C, Masa Jiménez JF, García Fernández J, et al. Clinical consensus recommendations regarding non-invasive respiratory support in the adult patient with acute respiratory failure secondary to SARS-CoV-2 infection. Med Intensiva. 2020 Oct 1;44(7):429–38.
[27] Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: Low risk of bio-aerosol dispersion. Vol. 55, European Respiratory Journal. European Respiratory Society; 2020.
[28] Crimi C, Pierucci P, Renda T, Pisani L, Carlucci A. High-Flow Nasal Cannula and COVID-19: A Clinical Review. Respir Care. 2022 Feb 1;67(2):227–40.
[29] Agarwal A, Basmaji J, Muttalib F, Granton D, Chaudhuri D, Chetan D, et al. High-flow nasal cannula for acute hypoxemic respiratory failure in patients with COVID-19: systematic reviews of effectiveness and its risks of aerosolization, dispersion, and infection transmission. Vol. 67, Canadian Journal of Anesthesia. Springer; 2020. p. 1217–48.